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Abstract
Background: Hepatitis C infection is a global public health issue. Chronic hepatitis C infection is associated with
significant morbidity and mortality. The aim of this study is to describe the costs for occupationally-cased hepatitis
C infections based on data from an accident insurance carrier.
Methods: This study is a secondary analysis based on the Database of a German Institution for Statutory Accident
Insurance. The analysis is based on a sample of insured parties whose hepatitis C infections were recorded as
occupational diseases between 1996 and 2013. The analysis is based on recognised hepatitis C cases and
incorporates records registered between 1 January 2000 and 31 December 2014.
Results: Within the study period, the number of reported and recognised hepatitis C cases declined by 73 and 86%
respectively. The majority of recognised hepatitis C cases (n = 1.121) were female, older than 40 years and were
active in a medical nursing profession. In the study period, the costs came to a total of € 87.9 million, of which 60%
was attributable to pension payments (€ 51,570,830) and around 15% was attributable to pharmaceutical and
medicinal products (€ 12,978,318). Expenses for drugs exhibited heavy increases in 2012 (from around € 500,000–
800,000 to € 1.7 million) and 2014 (to € 2.5 million) in particular. Pension payments came to € 1.6 million in
2000 and rose continuously to over € 4 million in 2014. Expenses for occupational rehabilitation accounted
for less than 1%.
Conclusions: For hepatitis C infections as an occupational disease, a considerable increase in costs has been
observed in recent years, while the number of reports has declined heavily. This rise in costs is explained by
the increase in pension payments and, since 2012, by a rise in the costs for drugs. The high costs of anti-viral
therapies is offset by the potential for considerable treatment benefits. Healing the infection is expected to
generate long-term cost savings for statutory accident insurance carriers, and also for social security systems.
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Background
The viral disease hepatitis C (HCV) is globally one of the
most common infectious diseases. The hepatitis C RNA
virus is transmitted from person to person, primarily
through contact with infected blood while the skin or mu-
cosa is also injured [1]. Healthcare personnel are at greater
risk of HCV infection due to the nature of their occupa-
tional duties [2]. The progression of the infection is often
non-specific, which is why the infection often remains un-
detected. Up to 85% of infections are chronic (HCV-RNA
positive longer than six months). According to data
from the World Health Organisation (WHO), around 150
million people globally have chronic hepatitis C (CHC);
700,000 people die each year as a result [1, 3, 4]. CHC is as-
sociated with a high level of morbidity and a diminished
quality of life. Up to 68% of patients suffer from symptoms
including fatigue, exhaustion, limited performance and sub-
clinical cognitive impairment. CHC is also associated with
an increased risk for developing cirrhosis of the liver and
hepatocellular carcinoma [4, 5]. A variety of extrahepatic
manifestations may also develop. The development of de-
pression symptoms, diabetes mellitus and malignant lym-
phoproliferative disorders such as follicular non-Hodgkin
lymphoma are associated with HCV. Several studies have
also indicated impairment of certain central nervous func-
tions and neurotransmission [4]. US scientists have calcu-
lated the costs for the US healthcare system associated with
CHC on the basis of data from a private health insurance
company. They (retrospectively) studied the insurance data
of 53,796 CHC patients over a period of eight years (2002–
2010), according to which the average cost attributable to
CHC per patient, per year was $ 24,176 (approx. € 21,776).
Stratified according to stages of the disease, these costs in-
crease as the disease progresses, reaching their peak in pa-
tients with terminal cirrhosis of the liver ($ 59,995/€ 53,880
per patient, per year) [6]. According to estimates, the share
of patients with manifest liver disease will quadruple over
the next 20 years without effective treatment [7]. Due to
the potentially severe progression of the disease and the
high associated costs, successful treatment of CHC is im-
portant [3, 6, 7]. The use of second-generation direct
anti-viral agents (DAAs) today provide promising treat-
ment combinations. Treatment of a CHC infection is con-
sidered successful if RNA viruses (HCV-RNA) can no
longer be detected in the blood between 12 and 24 weeks
after treatment is concluded [4, 5, 8]. As initial publica-
tions have shown, interferon-free DAA treatments have
achieved substantial sustained virological response rates
(SVRs) of over 90% in both treatment-naive and
treatment-experienced patients with CHC infections.
Such treatments are shorter than previous interferon-
based therapies, have fewer side effects, and are cur-
rently a recommended course of treatment for HCV
infections [3, 4].
The purpose of this study is to illustrate the costs for
occupational hepatitis C infections based on data of the
Institution for Statutory Accident Insurance and Preven-
tion in the Health and Welfare Services (Berufsgenos-
senschaft für Gesundheitsdienst und Wohlfahrtspflege,
BGW) for the period from 2000 to 2014.
Methods
This study is reported in line with A Consensus German
Reporting Standard for Secondary Data Analyses, Ver-
sion 2 (STROSA) [9].
Secondary data from BGW were used to analyse the costs
of occupational HCV infections. BGW’s occupational dis-
ease routine data records (BK-DOK) were used as a data
source.
Occupational disease procedure
In Germany, if there is reasonable cause to suspect an oc-
cupational disease (OD), physicians are required to submit
a report. Reports of suspected ODs may also be submitted
by health insurers, employers, representatives of company
interests or parties insured with the statutory accident in-
surance carriers. The statutory accident insurance carriers
will follow an investigative procedure to determine whether
a disease is an OD as defined by the Occupational Disease
Ordinance (Berufskrankheiten-Verordnung, BKV) (Section
9, para. 1 & 2 of the German Social Security Code VII). A
fully documented connection must be established here be-
tween the insured activity and the damaging exposure. The
disease must also be fully documented. There must be a
probable causal relationship between the exposure and the
disease.
In the case of infectious diseases, the exposure is often
difficult to identify, which is why it is sufficient to prove
that duties have been performed that are associated with
an elevated risk of infection. The performance of surgery
and contact with blood would be an example of such a
hazardous activity with an elevated risk for blood-borne
viral diseases. An occupational infectious disease can either
be classified as an insurance claim without entitlement to
pension disbursement (if the reduced work ability –RWA-
is less than 20%), or an entitlement to pension disburse-
ment can be recognised. If there is already a 10% RWA
from a previous insurance claim, a new 10% RWA can give
rise to a pension disbursement entitlement. In cases
where the OD suspicion has not been proven, a rejec-
tion is issued.
Documentation of OD reports
The key features of an OD suspicion report are regis-
tered in a standardised fashion in BK-DOK. OD suspi-
cion reports are fundamentally registered as reportable if
there are indications of an infection. This applies irre-
spective of which decision is taken under insurance law
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in the investigative procedure later. Because the investi-
gative procedure is time-consuming and a decision may
not be taken in the year of the OD report, the cases
ruled upon in a given reporting year can contain suspi-
cion reports from previous years.
Analysis
The analysis of the BK-DOK is based on data from insured
parties whose HCV infections were reported as suspected
ODs between 1996 and 2013. The sample was acquired
from the “Insurance Claims” database, which contains not
only fundamental personal data but also other details (in-
cluding sociodemographic features such as sex, year of
birth, industry, profession, diagnostic information, year of
registration, first and most recent decision, year of de-
cision, OD-triggering circumstances, insurance claim
reference number, etc.) The “Compensation Payments”
database provided data on expenses incurred on behalf of
the insured for drugs and benefits related to medical and
occupational rehabilitation.
Analysis of reduced work ability [RWA]
The RWA classification may change over the course of
the disease, depending on the severity of the disease at any
given time. The level of impairment and the dates on
which it starts and ends are documented for each change
in RWA. The analysis of the RWA is based on data from
1996 to 2014 and relates to the first established RWA and
the current RWA (as of 31 December 2014). For the pres-
entation of changes in the RWA, CHC patients were sorted
according to the current RWA (as of the analysis date) and
grouped according to the year of registration of the OD (in
five-year groups). Distribution of current RWAs in the re-
spective accident registration periods is presented using
percentiles.
Because data on compensation payments have only
been collected and processed since 2000, only registra-
tions falling between 1 January 2000 and 31 December
2014 are reflected. The registration titles were grouped
and reduced from 100 down to nine categories. In order
to represent changes in compensation payments, we have
allocated costs to medical rehabilitation (medicines, phar-
maceuticals, inpatient and outpatient treatment), occupa-
tional rehabilitation (phased return, retraining, etc.) and
pension payments (Fig. 2). The results are presented de-
scriptively (absolute and relative frequencies), and the in-
curred costs are added together over a reporting period of
15 years.
Data on insured parties is provided from within BGW
by the Rehabilitation Coordination department. It is de-
rived from the standardised occupational diseases records
and is analysed in anonymised form. Data were acquired
Fig. 1 Changes in mandatory reports for suspected hepatitis C and in recognised hepatitis C cases according to registration/reporting year
(1996–2013, BGW data)
Westermann et al. Journal of Occupational Medicine and Toxicology  (2016) 11:52 Page 3 of 8
in accordance with data protection regulations and with
the agreement of the BGW Data Protection Officer. The
data was analysed using the statistics software SPSS ver-
sion 23.
Results
In 1996 to 2013, a total of 3230 reports of suspected
cases of occupational HCV diseases were registered with
BGW. In the same period, infections were recognised as
ODs for 1121 insured parties. Across the study period,
the number of reported and recognised cases declined
by 73 and 86% respectively (Fig. 1).
Description of the sample (OD cases)
OD reports identified 1121 insured parties with an occu-
pational HCV. Mainly affected were female, older than
40 years of age and employed in hospitals. Over 90% of
the insured were engaged in a medical or nursing occupa-
tion at the time that they developed the disease (Table 1).
In the period under analysis, 42 deaths were recorded
as the result of an OD. Of those, one person was under
30 years of age, 16 (43%) were between 30 and 60 years of
age, while 25 (55%) were over the age of 61. The majority
of them (67%) were employed in hospitals, with just 21%
working in doctor’s practices and 11% in residential geriat-
ric care or rehabilitation clinics (no table).
Reduced work ability [RWA]
A total of 70% of insured parties (n = 779) had an initial
documented RWA in the analysis period from 1996 to
2014. The distribution of the degrees of RWA is shown
in Table 1. In 57% of cases, the RWA did not increase
during the period of their disease. In just under 40% of
cases, there were between two and four changes; only a
few had more than five changes. In one case, the RWA
changed twelve times.
Of 1121 cases, 75% had no RWA (as of the analysis date
of 31 December 2014) (Table 2). These include insured
parties who died in the period under analysis (1996 to
2013, n = 52). A RWA was established for 779 insured par-
ties over the course of the disease, although a RWA was
only in effect for 279 insured parties on the analysis date,
showing that 64% of the CHC patients only had a tempor-
ary RWA (500 of 779). Breaking down the entire reference
period into four intervals shows only minor differences in
the RWA grade. Only the 95th percentile and the max-
imum RWA are higher for cases registered before 2011
than for cases between 2011 and 2013 (40 versus 30% and
100 versus 50%).
Description of changes in expenses
Table 3 lists the payments and number of postings regis-
tered. For 98% of the recognised HCV cases, at least one
posting was registered during the period of 15 years (n =
1097). Most postings were attributable to outpatient treat-
ments (40%) and pension disbursements (37%). In the
period under analysis, compensation payments came to €
87.9 million, of which just under 60% were attributable to
pension payments (€ 51,570,830) and around 15% to
expenses for pharmaceuticals and other medicines (€
12,978,318).
Compensation payments for medical rehabilitation
(pharmaceuticals and other medicines), occupational re-
habilitation (phased returns, retraining, etc.) and pensions
Table 1 Description of the sample of insured parties with a
recognised hepatitis C infection according to sociodemographic
characteristics and the degree of reduced work ability (RWA) first
established (n = 1121)
Characteristics N %
Sex, female 838 75
Age (years)a
< 20 17 1
21–40 335 30
41–60 646 58
> 61 123 11
Field of work
Clinic/hospital 510 46
Doctor’s practice 341 30
Geriatric care/nursing 131 12





Medical assistant 266 24
Geriatric care assistant 84 8
Medical personnel 31 3
Administration 36 3
Social worker 19 2
Domestic services 17 1
RWA as %b
No RWA 342 30
RWA <20 3 0.4
RWA 20 493 63.2
RWA 30 127 16.3
RWA 40 64 8.2
RWA 50 35 4.5
RWA 60–80 37 4.7
RWA 100 20 2.6
Total 1121 100
aAge at the time of registration of the ODs reports
bValues relate to RWA as first established
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have developed differently over the 15-year period under
review (Fig. 2). Annual expenses rose from € 2.6 million to
€ 6.3 million between 2000 and 2005, remaining at an an-
nual € 6 million between 2005 and 2010 before then rising
to € 7.3 million and € 8.3 million in 2012 and 2014 re-
spectively. In all years except 2014, payments for medical
rehabilitation accounted for around one third, while ex-
penses for pensions accounted for around two thirds of
the costs. In 2014 on the other hand, expenses for medical
rehabilitation accounted for around half of expenditure.
Pension payments came to € 1.6 million in 2000 and rose
continuously to over € 4 million in 2014. Benefits aimed
at enabling involvement in working life (occupational re-
habilitation) accounted for less than 1% in all years.
Drugs for the treatment of hepatitis C
For the sample of recognised HCV cases, expenses for
drugs of € 255,730 in 2000 first rose continuously to
around € 1 million and remained at this level until 2010,
with the exception of 2007 (Fig. 3). A clear rise in ex-
penses for drugs was recorded for 2012 (to around € 1.7
million) and 2014 (to around € 2.5 million). Relative to
Table 2 Documented reduced work ability (RWA) as of the analysis date 31 December 2014 grouped by period of occupational
disease (OD) registration
RWA as % Year of OD registration (grouped)
1996 to 2000 2001 to 2005 2006 to 2010 2011 to 2013 Total
N % N % N % N % N %
No RWAa 357 77 289 74 154 73 42 71 842 75
010 1 0 0 0 1 0 0 0 2 0
020 58 13 53 14 26 12 11 19 148 13
030 15 3 20 5 13 6 4 7 52 5
040 9 2 7 2 5 2 0 0 21 2
050 9 2 5 1 7 3 2 3 23 2
060 4 1 7 2 1 0 0 0 12 1
070 5 1 4 1 0 0 0 0 9 1
080 1 0 1 0 1 0 0 0 3 0
100 2 0 5 1 2 1 0 0 9 1
Total 461 100 391 100 210 100 59 100 1,121 100
P 75 0 20 20 20 0
P 95 40 40 40 30 40
Max 100 100 100 50 100
aTotal deaths n = 52, of which 42 resulting from occupational disease (1996–2000 n = 18; 2001–2005 n = 14; 2006–2010 n = 8; 2011–2013 n = 2); not resulting from
occupational disease (1996–2000 n = 6; 2001–2005 n = 3; 2006–2010 n = 1)
Table 3 Accounting entry descriptions (grouped) according to number of cases, number of postings and expenses for recognised







Pensions 862 69,585 (37) 51,570,830 59
Pharmaceuticals and other medicines from pharmacies 619 9,897 (5) 12,978,318 14
Injury compensation, care allowances and other treatment costs 586 10,397 (6) 8,461,788 10
Inpatient treatment 543 1,669 (1) 5,460,608 6
Outpatient treatment (including treatment costs by physician) 921 74,376 (40) 4,812,063 6
Diagnosis costs 1,050 14,910 (8) 3,576,946 4
Benefits aimed at enabling involvement in working life (occupational rehabilitation) 49 1,310 (1) 730,423 1
Costs for resources 78 345 (0) 206,087 0
Reports 631 4,492 (2) 60,564 0
Totala 5,339b 186,981 (100) 87,857,627 100
aDoes not include combined invoices and payments received for rehabilitation (n = 19,445, 9%), bCases may arise in more than one posting description (e.g., costs
for treatments, reports and pharmaceuticals)
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the annual costs incurred for the years 2005 to 2010, the
increase in costs for drugs was over 70% in 2012 and
over 120% in 2014.
Discussion
Among German healthcare personnel workers, both re-
ported and recognized occupational HCV infections de-
creased over the study period, yet costs associated with
HCV increased. The majority of claims was represented by
females aged 40 years and older who were employed as
nurses in hospitals. The anti-HCV prevalence in the gen-
eral population in Germany is estimated to be stable at a
low level (0.3%) [10]. The number of reported OD cases
among healthcare personnel in Germany declined over the
time possibly due to improved blood-borne pathogen
handling practices. Guidelines have been issued since 2000
that aim to prevent exposure to blood, for example, from
NSI [11]. In the mid-1990s it came to a strong increase in
reported ODs, probably in many cases linked to old cases,
as a result of increased investigations since the mid-1990s
in Germany [12]. In addition, the number of reported and
recognized ODs may not reflect the real number of
HCV infection cases among healthcare personnel. Nee-
dlestick injuries (NSI) are the most frequently reported
occupational accidents in healthcare [13]. The results
of epidemiological studies indicate that most of HCWs
(80%) have been affected by NSI, and many such injur-
ies remain unreported [11].
Fig. 2 Payments for medical, occupational rehabilitation and pensions for recognised HCV cases; 1097 cases between 2000 and 2014
Fig. 3 Expenses for drugs for the sample of recognised HCV cases listed by posting year
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Despite lower OD HCV prevalence, the costs related to
occupational exposure have increased. The costs for CHC
are largely defined by the rising expenses for pensions. In
2012 to 2014, however, there was a strong rise in each case
in costs for drug therapy. This likely associated with ex-
penses for triple combinations of pegylated interferon, riba-
virin and one of the two first-generation protease inhibitors,
boceprevir and telaprevir in 2012. The rise in expenses in
2014 is probably attributable to the use of new direct anti-
viral agents (DAAs, second-generation protease inhibitors)
for the treatment of HCV infections.
Initial research results on the new DAAs indicate sus-
tainable SVR rates with shorter treatment periods and a
tendency for fewer side effects [4]. DAAs initially involve
higher expenses, but may reduce long term treatment costs
as reported by Nevens et al. [14]. SVR rates are associated
with a reduction in CHC-caused (hepatic and extrahepatic)
morbidity and mortality [15, 16]. Functional improvements
in the cirrhosis were observed through the SVRs, as were
sustained successes in the treatment of extrahepatic com-
plications [4, 8]. CHC remains the most frequent indication
for liver transplantation [17]. Preoperative treatment to
achieve an SVR at the time of transplantation sustainably
reduces the risk of the transplanted organ being infected
with the HCV [15, 17]. Early identification of an infection
is a key factor in enabling the patient to recover as fully as
possible. The treatment of patients in less severe stages of
the disease using DAA therapy is costly, but is likely to be
successful in preventing future advanced liver diseases that
are also associated with high expense [6]. Nevens et al. also
observed a considerable reduction in the costs in cases
where an SVR was achieved in the mild, less pronounced
phases of CHC [14]. In the long term, the high costs of this
treatment are likely to pay off by allowing early treatment
of CHC infections to reduce morbidity and mortality rates.
The case figures presented here do not provide a complete
picture of the costs for occupation HCV infections in
Germany. The BGW database used here only contains OD
reports on employees from non-government institutions.
Those restrictions that generally apply for secondary data
apply to this register data. The data is not clinical in nature,
but rather administrative with limited sociodemographic
characteristics present. As in table one reported, nurses are
the largest represented demographic group among the
healthcare professionals with an HCV infection as OD.
This data was not corrected for the total population be-
cause it was not possible to get the necessary information,
with the same corresponding to the age groups presented.
Although this lack of data adjustment is an inherent limita-
tion of our study, a positive feature of this data is that it
provides a longitudinal perspective, enabling the claiming
of insurance benefits as relevant outcome (e.g., in the form
of compensation payments) to be observed over a suffi-
ciently long period of time.
Conclusions
For hepatitis C infections as an OD, a considerable in-
crease in costs has been observed, while the number of
cases has declined heavily. These costs are explained by the
increase in pension payments and, since 2012, by a rise in
the costs for drugs. The use of DAA treatments is currently
fundamentally changing disease management for CHC pa-
tients. The high costs of the treatments might be offset by
the potentially considerable benefits. The optimum solution
is successful therapy at as early a stage in the disease as
possible in order to preserve the health-related quality of
life of the insured as fully as possible, thereby also preserv-
ing their ability to work. The resultant reduction in con-
comitant hepatic and extrahepatic diseases will potentially
result in lower RWA gradings in the long term among the
overall insured population. In the long run, maintaining the
ability to work would generate overall cost savings for acci-
dent insurers and also for the other social security systems.
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